1Malabarba A,Goldstrein BP.Origin,structure,and activity in vitro and in vivo of dalbavancin[J].J Antimicrob Chemother,2005,55 (Suppl2):ii15-ii20.
2Streit JM,Fritsche TR,Sader HS,et al.Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates[J].Diagn Microbiol Infect Dis,2004,48:137-143.
3Streit JM,Sader HS,Fritsche TR,et al.Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens[J].Diagn Microbiol Infect Dis,2005,53:307-310.
4Bozdogan B,Esel D,Whitener C,et al.Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center[J].J Antimicrob Chemother,2003,52:864-868.
5Candiani G,Abbondi M,Borgonovi M,et al.In-vitro and in-vivo antibacterial activity of BI397,a new semi-synthetic glycopeptide antibiotic[J].J Antimicrob Chemother,1999,44:179-192.
6Darouiche RO,Mansouri MD.Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo[J].J Infect,2005,50:206-209.
7Dorr MB,Jabes D,Cavaleri M,et al.Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin,a semi-synthetic glycopeptide[J].J Antimicrob Chemother,2005,55 (Suppl 2):ii25-ii30.
8Leighton A,Gottlieb AB,Dorr MB,et al.Tolerability,pharmacokinetics,and serum bactericidal activity of intravenous dalbavancin in healthy volunteers[J].Antimicrob Agents Chemother,2004,48:940-945.
9Cavaleri M,Riva S,Valagussa A,et al.Pharmacokinetics and excretion of dalbavancin in the rat[J].J Antimicrob Chemother,2005,55 (Suppl 2):ii31-ii35.
10Seltzer E,Dorr MB,Goldstein BP,et al.Once-weekly dalbavancin versus standard-of -care antimicrobial regimens for treatment of skin and soft-tissue infections[J].Clin Infect Dis,2003,37:1298-1303.
2Zinner S H. Antibiotic use: present and future[J]. New Microbiol, 2007, 30(3): 321-325.
3Kahne D, Leimkuhler C, Lu W, et al. Glycopeptide and lipogylcopeptide antibiotics[J]. Chem Rev, 2005, 105(2): 425 -448.
4Zou Y, Brunzelle J S, Nair S K. Crystal structures of lipoglycopvptide antibiotic deacetylases: implications for the biosynthesis of A40926 and toicoplanin[J]. Chem Biol, 2008, 15(6): 533-545.
5Goldstein B P, Sclva E, Gastaldo L, et al. A40926, a new glycopcptidc antibiotic with anti-Neisseria activity [J]. AntimicrobAgents Chemother, 1987, 31(12): 1961-1966.
6Gunnarsson N, Bruheim P, Nielsen J. Glucose metabolism in the antibiotic producing actinomycetc Nonomuraea sp. ATCC 39727 [J]. Biotechnol Bioeng, 2004, 88(5): 652-663.
7Sosio M, Stinchi S, Beltrametti F, et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by Nonomuraea species [J]. Chem Biol, 2003, 10(6): 541-549.
8Sosio M, Donadio S. Understanding and manipulating glycopeptide pathways: the example of the dalbavancin precursor A40926[J]. Jlnd Microbiol Biot, 2006, 33,569-576.
9Borghi A, Edwards D, Franco Z, et al. Factors affecting the normal and branched-chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus[J]. J General Microbiol, 1991, 137(3): 587-592.
10Zerilli L F, Edwards D M, Borghi A, et al. Determination of the acyl moieties of the antibiotic complex A40926 and their relation with the membrane lipids of the producer strain[J]. Rapid Commun Mass Spectrum, 1992, 6(2): 109-114.
